← Back to Screener
Relmada Therapeutics, Inc. Common Stock (RLMD)
Price$5.95
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)24.00%
Price vs S&P 500 (4W)-18.71%
VGM Score77.55
Market Capitalization$624.10M
All Metrics
Book Value / Share (Quarterly)$2.09
P/TBV (Annual)0.62x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.41
Price vs S&P 500 (YTD)15.03%
EPS (TTM)$-1.15
10-Day Avg Trading Volume0.89M
EPS Excl Extra (TTM)$-1.15
EPS (Annual)$-1.45
ROI (Annual)-66.33%
Gross Margin (Annual)0.00%
Cash / Share (Quarterly)$2.23
ROA (Last FY)-61.05%
EBITD / Share (TTM)$-1.13
ROE (5Y Avg)-115.89%
Cash Flow / Share (Annual)$-0.62
P/B Ratio2.85x
P/B Ratio (Quarterly)3.34x
Net Income / Employee (Annual)$-3,375,600
Net Interest Coverage (TTM)-72.04x
ROA (TTM)-64.46%
EPS Incl Extra (Annual)$-1.45
Current Ratio (Annual)14.62x
Quick Ratio (Quarterly)18.15x
3-Month Avg Trading Volume1.52M
52-Week Price Return625.61%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$3.40
P/S Ratio (Annual)62409.69x
52-Week High$8.00
EPS Excl Extra (Annual)$-1.45
26-Week Price Return31.93%
Quick Ratio (Annual)14.46x
13-Week Price Return34.31%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)18.26x
Enterprise Value$614.32M
Book Value / Share Growth (5Y)-28.87%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-500.00%
Cash / Share (Annual)$1.27
3-Month Return Std Dev137.40%
Net Income / Employee (TTM)$-3,463,400
ROE (Last FY)-66.33%
Net Interest Coverage (Annual)-48.51x
EPS Basic Excl Extra (Annual)$-1.45
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.15
ROI (TTM)-71.22%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$4.67
Price vs S&P 500 (52W)601.24%
Year-to-Date Return23.19%
5-Day Price Return-13.14%
EPS Normalized (Annual)$-1.45
ROA (5Y Avg)-99.18%
Net Profit Margin (Annual)-500.00%
Month-to-Date Return-17.48%
Cash Flow / Share (TTM)$-3.71
EBITD / Share (Annual)$-1.50
Operating Margin (Annual)-500.00%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-115.89%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.15
P/TBV (Quarterly)2.00x
P/B Ratio (Annual)4.09x
Book Value / Share (Annual)$1.18
Price vs S&P 500 (13W)26.06%
Beta0.48x
Revenue / Share (TTM)$0.00
ROE (TTM)-71.22%
52-Week Low$0.52
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.22est. -0.20
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.33
4.33
4.27
4.27
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
RLMDRelmada Therapeutics, Inc. Common Stock | — | — | B | $5.95 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Relmada Therapeutics is a clinical-stage biotech company developing esmethadone (REL-1017), an oral NMDA receptor antagonist for depression and other central nervous system disorders. The company is focused on addressing high unmet medical needs in CNS disease treatment through novel drug formulations.